TriangleDISEASE & TREATMENT SETTING
Aromasin: advanced Breast cancer after prior therapy
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
1.2 Advanced Breast Cancer in Postmenopausal Women AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].
Broader topic: Breast Cancer
- Source population
- Not part of this definition
- Disease extent
- advanced
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- class
- following tamoxifen therapy [see Clinical Studies (14
- status
- required
- derivation status
- source-attested
- derivation note
- Scoped from the FDA approved indication for Aromasin (product label). Only dimensions stated in that wording are part of this definition.
- source wording
- 1.2 Advanced Breast Cancer in Postmenopausal Women AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].
Study evidence for this setting
No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.
Source relationships and population-mapping limitations
- bindings
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice